Healthcare specialist Apposite Capital acquires specialist CRO 1MED. The advisors

Apposite Capital, healthcare specialist private equity investor, announced its acquisition of 1MED, the Swiss based Contract Research Organization (CRO) for an undisclosed amount. Apposite Capital will work with the 1MED management team to continue to strengthen and widen the company’s service offering and further expand its geographic coverage.

 

The legal advisors team

Baker McKenzie advised Apposite Capital on all Swiss law and English law aspects relating to the financing of the acquisition of 1MED. The team was led by Samuel Marbacher (pictured top left) and Philip Spoerlé (pictured top right) and further comprised Manuel Meyer, Cora Schmid and Manuel Hirlinger along with a team of lawyers from Baker McKenzie London office.

Advisers to Apposite Capital also included:  EY (accounting, tax and legal), PMSI (commercial), FRP (debt advisory), Trowers & Hamlins (legal) and Aon (W&I, Insurance)

Fidinam & Partners acted as part of the legal advising team for 1MED with a team including Christian Ballabio (managing partner) and Giuseppe Lerose (M&A tax). Advisers to 1MED also included: Credit Suisse (financial advisor to shareholders of 1MED), Lexsential (legal), Druces (legal).

Credit Suisse  acted as financial advisor to shareholders of 1MED. In this transaction, Credit Suisse was in turn advised by Niederer Kraft Frey (NKF). NKF team was led by M&A and Finance partners Till Spillmann and Adrian Koller, working with junior associates Reto Seiler as well as partner Markus Kronauer (Tax).

Advisers to 1MED also included:  Lexsential (legal), Druces (legal).

The companies

Apposite Capital is an independent investment firm focused exclusively on healthcare. It focuses on companies operating in health and social care, medtech & medical products, pharmaceuticals & life science and digital health.  Apposite was established in 2006 and is headquartered in London, UK.

1MED is a specialist Contract Research Organization (CRO) that supports the commercialization of new medical technologies and products by providing regulatory strategy, clinical trial management and quality assurance services across a broad range of therapeutic areas and product types. The company was created in 2014 and is headquartered in Agno, Switzerland.

 

 

FabioAdmin

SHARE